How to Foster Communication Among all Members of the Cancer Care Team with Pathologists to Deliver Individualized Treatment for Patients with Lung Cancer

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.

Related Videos

October 23, 2018

The Role of Tumor Mutational Burden in Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

October 16, 2015

Hot Topics in Treating Cutaneous Malignancies

Dr. Sanjiv Agarwala identifies the newest developments in treatments for melanoma, cutaneous T-cell lymphoma, Merkel cell carcinoma, squamous-cell carcinoma, and invasive-cell carcinoma.